FilingReader Intelligence

Hubei Biocause Pharmaceutical faces second delisting warning

July 21, 2025 at 10:39 AM UTCBy FilingReader AI

Hubei Biocause Pharmaceutical received a second delisting risk warning after failing to disclose its 2024 annual report and 2025 first-quarter report within statutory deadlines.

The company faces potential delisting if it doesn't file the 2024 annual report, verified by over half its directors, within two months. China's securities regulator launched an investigation in May over the delayed filings.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Hubei Biocause Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →